Level C· Early human research exploring benefitsCase Report / SeriesEurope PMCOpen access

Secretome-Assisted Regenerative Therapy for Hyaluronic Acid Filler-Induced Vascular Occlusion: A Case Report

Sanchez Tovar J., Fregoso Sandoval JL.

Case Report / Series on Scar, published in Cureus (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Cureus (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41728415
PMCID
PMC12922461
DOI
10.7759/cureus.101978

Abstract (original English)

Hyaluronic acid (HA) fillers are widely used for non-surgical facial contouring, but vascular occlusion remains one of the most feared complications due to its potential to cause necrosis, functional impairment, and permanent deformities. Conventional management focuses on high-dose hyaluronidase and supportive therapy, which may not always prevent long-term sequelae. In recent years, regenerative approaches such as secretome and mesenchymal stem cell (MSC) therapies have emerged as promising alternatives. We report the case of a 29-year-old woman who developed nasal vascular occlusion following HA filler injection by a non-medical injector. Initial presentation included localized pain and cutaneous necrosis in the nasal tip. Early management involved repeated hyaluronidase infiltration, oral sildenafil, a single dose of prednisone, and adjuvant intravenous peroxidation therapy. Subsequently, 12 local applications of standardized MSC-derived secretome were administered. This strategy promoted granulation tissue formation, re-epithelialization, and partial recovery of skin integrity. However, clinical persistence of nasal asymmetry suggested cartilage involvement. To address this, an additional injection of 10 million MSCs was performed, leading to stable cutaneous coverage and improvement of nasal contour within 45 days. At the two-year follow-up, the patient showed a stable sc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research